Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

Guido Cavaletti, David R. Cornblath, Ingemar S. J. Merkies, Tjeerd J. Postma, Emanela Rossi, Paola Alberti, Jordi Bruna, Andreas A. Argyriou, Chiara Briani, Roser Velasco, Haralabos P. Kalofonos, Dimitri Psimaras, Damien Ricard, Catharina G. Faber, Roy I. Lalisang, Dieta Brandsma, Susanne Koeppen, Simon Kerrigan, Angelo Schenone, Wolfgang Grisold & 6 others Anna Mazzeo, Luca Padua, Susan G. Dorsey, Marta Penas-Prado, Maria G. Valsecchi, the CI-PeriNomS Group

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation (“impossible”) generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51%-65% of patients; 76%-78% of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84% to 100%; some degree of motor impairment occurred in 43%-56% of them. In Group 3 strength reduction was observed in 49%-50% and sensory perception was altered in up to 82%. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.
Original languageEnglish
Pages (from-to)111-119
JournalJournal of the Peripheral Nervous System
Volume24
Issue number1
DOIs
Publication statusPublished - 1 Mar 2019

Cite this

Cavaletti, G., Cornblath, D. R., Merkies, I. S. J., Postma, T. J., Rossi, E., Alberti, P., ... the CI-PeriNomS Group (2019). Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 24(1), 111-119. https://doi.org/10.1111/jns.12306
Cavaletti, Guido ; Cornblath, David R. ; Merkies, Ingemar S. J. ; Postma, Tjeerd J. ; Rossi, Emanela ; Alberti, Paola ; Bruna, Jordi ; Argyriou, Andreas A. ; Briani, Chiara ; Velasco, Roser ; Kalofonos, Haralabos P. ; Psimaras, Dimitri ; Ricard, Damien ; Faber, Catharina G. ; Lalisang, Roy I. ; Brandsma, Dieta ; Koeppen, Susanne ; Kerrigan, Simon ; Schenone, Angelo ; Grisold, Wolfgang ; Mazzeo, Anna ; Padua, Luca ; Dorsey, Susan G. ; Penas-Prado, Marta ; Valsecchi, Maria G. ; the CI-PeriNomS Group. / Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. In: Journal of the Peripheral Nervous System. 2019 ; Vol. 24, No. 1. pp. 111-119.
@article{f81538bc57ef47d5aeb52c6fab69112e,
title = "Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity",
abstract = "To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation (“impossible”) generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51{\%}-65{\%} of patients; 76{\%}-78{\%} of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84{\%} to 100{\%}; some degree of motor impairment occurred in 43{\%}-56{\%} of them. In Group 3 strength reduction was observed in 49{\%}-50{\%} and sensory perception was altered in up to 82{\%}. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.",
author = "Guido Cavaletti and Cornblath, {David R.} and Merkies, {Ingemar S. J.} and Postma, {Tjeerd J.} and Emanela Rossi and Paola Alberti and Jordi Bruna and Argyriou, {Andreas A.} and Chiara Briani and Roser Velasco and Kalofonos, {Haralabos P.} and Dimitri Psimaras and Damien Ricard and Andrea Pace and Faber, {Catharina G.} and Lalisang, {Roy I.} and Dieta Brandsma and Susanne Koeppen and Simon Kerrigan and Angelo Schenone and Wolfgang Grisold and Anna Mazzeo and Luca Padua and Dorsey, {Susan G.} and Marta Penas-Prado and Valsecchi, {Maria G.} and {the CI-PeriNomS Group} and Faber, {C. G.} and B. Frigeni and F. Lanzani and L. Mattavelli and Piatti, {M. L.} and D. Binda and P. Bidoli and M. Cazzaniga and D. Cortinovis and E. Gali{\`e} and M. Campagnolo and A. Salvalaggio and M. Ruiz and Vanhoutte, {E. K.} and W. Boogerd and J. Hense and R. Grant and D. Storey and L. Reni and C. Demichelis and A. Pessino and G. Granata and Heimans, {J. J.} and Meijer, {R. J.}",
year = "2019",
month = "3",
day = "1",
doi = "10.1111/jns.12306",
language = "English",
volume = "24",
pages = "111--119",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "1",

}

Cavaletti, G, Cornblath, DR, Merkies, ISJ, Postma, TJ, Rossi, E, Alberti, P, Bruna, J, Argyriou, AA, Briani, C, Velasco, R, Kalofonos, HP, Psimaras, D, Ricard, D, Faber, CG, Lalisang, RI, Brandsma, D, Koeppen, S, Kerrigan, S, Schenone, A, Grisold, W, Mazzeo, A, Padua, L, Dorsey, SG, Penas-Prado, M, Valsecchi, MG & the CI-PeriNomS Group 2019, 'Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity' Journal of the Peripheral Nervous System, vol. 24, no. 1, pp. 111-119. https://doi.org/10.1111/jns.12306

Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. / Cavaletti, Guido; Cornblath, David R.; Merkies, Ingemar S. J.; Postma, Tjeerd J.; Rossi, Emanela; Alberti, Paola; Bruna, Jordi; Argyriou, Andreas A.; Briani, Chiara; Velasco, Roser; Kalofonos, Haralabos P.; Psimaras, Dimitri; Ricard, Damien; Faber, Catharina G.; Lalisang, Roy I.; Brandsma, Dieta; Koeppen, Susanne; Kerrigan, Simon; Schenone, Angelo; Grisold, Wolfgang; Mazzeo, Anna; Padua, Luca; Dorsey, Susan G.; Penas-Prado, Marta; Valsecchi, Maria G.; the CI-PeriNomS Group.

In: Journal of the Peripheral Nervous System, Vol. 24, No. 1, 01.03.2019, p. 111-119.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity

AU - Cavaletti, Guido

AU - Cornblath, David R.

AU - Merkies, Ingemar S. J.

AU - Postma, Tjeerd J.

AU - Rossi, Emanela

AU - Alberti, Paola

AU - Bruna, Jordi

AU - Argyriou, Andreas A.

AU - Briani, Chiara

AU - Velasco, Roser

AU - Kalofonos, Haralabos P.

AU - Psimaras, Dimitri

AU - Ricard, Damien

AU - Pace, Andrea

AU - Faber, Catharina G.

AU - Lalisang, Roy I.

AU - Brandsma, Dieta

AU - Koeppen, Susanne

AU - Kerrigan, Simon

AU - Schenone, Angelo

AU - Grisold, Wolfgang

AU - Mazzeo, Anna

AU - Padua, Luca

AU - Dorsey, Susan G.

AU - Penas-Prado, Marta

AU - Valsecchi, Maria G.

AU - the CI-PeriNomS Group

AU - Faber, C. G.

AU - Frigeni, B.

AU - Lanzani, F.

AU - Mattavelli, L.

AU - Piatti, M. L.

AU - Binda, D.

AU - Bidoli, P.

AU - Cazzaniga, M.

AU - Cortinovis, D.

AU - Galiè, E.

AU - Campagnolo, M.

AU - Salvalaggio, A.

AU - Ruiz, M.

AU - Vanhoutte, E. K.

AU - Boogerd, W.

AU - Hense, J.

AU - Grant, R.

AU - Storey, D.

AU - Reni, L.

AU - Demichelis, C.

AU - Pessino, A.

AU - Granata, G.

AU - Heimans, J. J.

AU - Meijer, R. J.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation (“impossible”) generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51%-65% of patients; 76%-78% of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84% to 100%; some degree of motor impairment occurred in 43%-56% of them. In Group 3 strength reduction was observed in 49%-50% and sensory perception was altered in up to 82%. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.

AB - To test if and how chemotherapy-induced peripheral neurotoxicity (CIPN) is perceived differently by patients and physicians, making assessment and interpretation challenging. We performed a secondary analysis of the CI-PeriNomS study which included 281 patients with stable CIPN. We tested: (a) the association between patients' perception of activity limitation in performing eight common tasks and neurological impairment and (b) how the responses to questions related to these daily activities are interpreted by the treating oncologist. To achieve this, we compared patients' perception of their activity limitation with neurological assessment and the oncologists' blind interpretation. Distribution of the scores attributed by oncologists to each daily life maximum limitation (“impossible”) generated three groups: Group 1 included limitations oncologists attributed mainly to motor impairment; Group 2 ones mainly attributed to sensory impairment and Group 3 ones with uncertain motor and sensory impairment. Only a subset of questions showed a significant trend between severity in subjective limitation, reported by patients, and neurological impairment. In Group 1, neurological examination confirmed motor impairment in only 51%-65% of patients; 76%-78% of them also had vibration perception impairment. In Group 2, sensory impairment ranged from 84% to 100%; some degree of motor impairment occurred in 43%-56% of them. In Group 3 strength reduction was observed in 49%-50% and sensory perception was altered in up to 82%. Interpretation provided by the panel of experienced oncologists was inconsistent with the neurological impairment. These observations highlight the need of a core set of outcome measures for future CIPN trials.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061269274&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30672664

U2 - 10.1111/jns.12306

DO - 10.1111/jns.12306

M3 - Article

VL - 24

SP - 111

EP - 119

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 1

ER -